Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes
暂无分享,去创建一个
Merlin C. Thomas | M. Woodward | G. Hillis | B. Williams | V. Perkovic | Merlin C Thomas | M. Marre | J. Chalmers | B. Neal | M. Cooper | S. Zoungas | Qiang Li | R. Pickering | M. Thomas
[1] B. Astor,et al. Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] M. Woodward,et al. Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial , 2014, Diabetes Care.
[3] Merlin C. Thomas,et al. Glycemic exposure, glycemic control, and metabolic karma in diabetic complications. , 2014, Advances in chronic kidney disease.
[4] M. Woodward,et al. Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study , 2014, Diabetes.
[5] Mark Woodward,et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes , 2013, Diabetes Care.
[6] B. Astor,et al. sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death , 2013, Diabetes.
[7] I. Shimomura,et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. , 2013, Atherosclerosis.
[8] M. Cooper,et al. Mechanisms of diabetic complications. , 2013, Physiological reviews.
[9] Paul J Thornalley,et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy , 2012, Nature Medicine.
[10] G. Hitman,et al. Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes , 2011, Diabetes.
[11] C. Forsblom,et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes , 2011, Diabetologia.
[12] Lloyd E Chambless,et al. Several methods to assess improvement in risk prediction models: Extension to survival analysis , 2011, Statistics in medicine.
[13] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[14] S. Yamagishi,et al. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. , 2010, Frontiers in bioscience.
[15] H. Parving,et al. Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes , 2010, Diabetes.
[16] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[17] N. Calcutt,et al. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials , 2009, Nature Reviews Drug Discovery.
[18] A. Khera,et al. Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis , 2009, Diabetes Care.
[19] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[20] E. Kojro,et al. Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases* , 2008, Journal of Biological Chemistry.
[21] M. Cooper,et al. UKPDS and the legacy effect. , 2008, The New England journal of medicine.
[22] P. Massin,et al. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. , 2008, Diabetes & metabolism.
[23] Merlin C. Thomas,et al. Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.
[24] Y. Tomino,et al. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. , 2008, Diabetes research and clinical practice.
[25] T. Imaizumi,et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. , 2008, Microvascular research.
[26] R. Ramasamy,et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. , 2008, The Journal of clinical investigation.
[27] T. Zima,et al. Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene. , 2008, Archives of physiology and biochemistry.
[28] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[29] Takafumi Yoshida,et al. Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes , 2007, Molecular medicine.
[30] Ann Marie Schmidt,et al. Advanced glycation end products: sparking the development of diabetic vascular injury. , 2006, Circulation.
[31] Merlin C. Thomas,et al. Interactions between renin angiotensin system and advanced glycation in the kidney. , 2005, Journal of the American Society of Nephrology : JASN.
[32] S. Jacqueminet,et al. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. , 2005, Clinical chemistry.
[33] A. D'Angelo,et al. Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[34] T. Kislinger,et al. RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice , 2002, Circulation.
[35] R. Collins,et al. Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation , 2001 .
[36] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[37] Advance Management Committee. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation , 2001, Diabetologia.
[38] R. LaBrie,et al. A 12-year follow-up study of chronic schizophrenics. , 1982, Hospital & community psychiatry.